The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of years thanks to new technologies, former U.S. Treasury Secretary ...

In a press release, GlobalData pharma analyst Costanza Alciati said, “From the start, Zepbound emerged as the primary new competitor of Wegovy, and it seems that Eli Lilly has followed in some way ...

said in the news release. "We hope this will spark more meaningful conversations between patients and health care providers and ultimately lead to better health outcomes." Zepbound is a dual ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

and fulfilling its statutory mandate to maintain an “up-to-date” drug shortage list, among other things. This order relates to certain FDA-approved Mounjaro and Zepbound products. The Mounjaro ...

Zepbound is a prescription injectable medication ... comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed ...